Bringing academia and industry together at Yorkshire Bio-Partnering

Bringing academia and industry together at Yorkshire Bio-Partnering

Published on 27/04/2022
Bringing academia and industry together at Yorkshire Bio-Partnering

The University of Bradford Faculty of Life Sciences extended a warm welcome to 80 attendees on 13th April for the inaugural Yorkshire Bio-Partnering event, which brought together academia and industry, with a focus on healthcare innovation and bioscience.

With the Yorkshire region and the M62 corridor being home to many innovative companies in the healthcare and bioscience sector, the event celebrated specialist expertise and collaboration in pharmaceuticals, diagnostics, nutraceuticals and specialty ingredients. The importance of translational research activities between industry, NHS and academia was highlighted, as a way of promoting innovation and entrepreneurship, increasing research funding, and making a valuable contribution the growth of the UK economy.

The event’s agenda highlighted successful partnerships through keynote speeches and selected case studies, promoted funding and support available through a series of presentations and encouraged networking both informally and through 1-2-1 partnering activities.

The keynote speakers were Prof Mark Hull from University of Leeds School of Medicine, who spoke about cancer prevention research in the region, followed by Dr Dana Koludrovic at Cancer Research UK’s presentation on translational research at the charity. The final speaker, Dr Liz Mear, the Non-Exec Director of Health Education England and SBRI Chair, discussed start-up strategy with “Think big, start small, scale fast”.

Bionow’s Executive Director of Business Development, Stella James, commented: “It was fantastic to see such a great turnout for the first Yorkshire Bio-Partnering conference, with excellent opportunities to learn, network and forge potential new partnerships. We aim to build on this initial success with future events.”

The Yorkshire Bio-Partnering event was sponsored by Avacta Life Sciences, Turnbull Lynch IP, CrystecPharma and Incanthera.

Our Valued Sponsors & Partners